ATOS Atossa Genetics Inc.

0.49
-0.03  -6%
Previous Close 0.52
Open 0.54
Price To book 2.04
Market Cap 5714805
Shares 11,701,075
Volume 1,071,958
Short Ratio 2.23
Av. Daily Volume 1,344,287

SEC filingsSee all SEC filings

  1. S-3 - Registration statement under Securities Act of 1933 171097686
  2. 8-K - Current report 171085264
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171031606
  4. 8-K - Current report 171031231
  5. 424B3 - Prospectus [Rule 424(b)(3)] 17945190

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 enrollment to be completed by August 2017.
Fulvestrant
Cuctal carcinoma in situ(DCIS) - invasive breast cancer

Latest News

  1. Atossa Genetics, Endoxifen Phase I Results and Pipeline Review
  2. Atossa Genetics Announces Preliminary Results from Phase 1 Study of Topical Endoxifen
  3. Today's Research Reports on Stocks to Watch: Atossa Genetics and Forward Pharma
  4. Atossa Genetics To Host Conference Call to Announce Preliminary Results from Phase 1 Study of Topical Endoxifen Thursday, September 14, 2017 at 2 pm EDT
  5. "Meeting Or Exceeding Expectations"
  6. Atossa Genetics Announces Second Quarter 2017 Financial Results And Provides Company Update
  7. Vista Partners Publishes July 2017 Macroeconomic & Investment Newsletter
  8. Atossa Genetics Completes Enrollment in Endoxifen Phase 1 Study and Provides Update on Fulvestrant Microcatheter Phase 2 Study
  9. Atossa Genetics Announces Warrant Exercises
  10. Atossa Genetics Receives Positive Safety Committee Assessment of First Cohort Receiving Oral Formulation of Endoxifen in Phase 1 Dose Escalation Study
  11. ATOS: Balance Sheet Boosted by Recent Financing
  12. Atossa Genetics to Present at the LD Micro Invitational on June 6, 2017
  13. Atossa Genetics Completes Enrollment in Topical Arm of Endoxifen Phase 1 Study
  14. Atossa Genetics Announces First Quarter 2017 Financial Results and Provides Company Update
  15. Atossa Genetics Receives Second Positive Safety Committee Decision in Phase 1 Topical Endoxifen Dose Escalation Study
  16. Atossa Genetics Receives Approval from Institutional Review Board for Continuation of its Fulvestrant Microcatheter Phase 2 Study
  17. Atossa Genetics Receives Positive Interim Review From Independent Safety Committee in Phase 1 Endoxifen Dose Escalation Study
  18. Atossa Genetics Enrolls First Cohort of Eight Subjects in Endoxifen Study
  19. Atossa Genetics Closes Public Offering
  20. Seattle breast cancer company stock plummets as it seeks funding to continue operations

SEC Filings

  1. S-3 - Registration statement under Securities Act of 1933 171097686
  2. 8-K - Current report 171085264
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171031606
  4. 8-K - Current report 171031231
  5. 424B3 - Prospectus [Rule 424(b)(3)] 17945190
  6. 8-K - Current report 17940535
  7. 8-K - Current report 17887198
  8. 8-K - Current report 17835429
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 17835403
  10. DEF 14A - Other definitive proxy statements 17759222